TRPMS to Improve Mobility and Depression in Multiple Sclerosis

Last updated: December 22, 2023
Sponsor: NYU Langone Health
Overall Status: Trial Not Available

Phase

N/A

Condition

Multiple Sclerosis

Memory Loss

Neurologic Disorders

Treatment

Computerized CT (Cognitive Training)

TRPMS (Transcranial Rotating Permanent Magnet Stimulation)

Aerobic Exercise Program

Clinical Study ID

NCT04578041
20-01101
  • Ages 18-70
  • All Genders

Study Summary

This study is aimed to test the efficacy of 10 sessions of Transcranial Rotating Permanent Magnetic Stimulation (TRPMS) paired with aerobic exercise or computerized cognitive training (CT) on mobility and depression symptoms in 40 individuals affected by multiple sclerosis (MS).

Participants in Arm 1 will complete 10x40 minutes daily sessions of TRPMS+aerobic exercise. Participants in Arm 2 will complete TRPMS+computerized CT. Primary outcomes for both arms will be assessed at baseline, at treatment end and after 4-week from the treatment end (follow-up).

Eligibility Criteria

Inclusion

Inclusion Criteria: In order to be eligible to participate in Arm 1 of this study, an individual must meet allof the following criteria:

  1. Between ages 18 - 70
  2. SDMT z-score ≥ -3.0
  3. Wide Range Achievement Test-4th Edition (WRAT-4) Reading Recognition scaled score ≥ 85
  4. Definite MS diagnosis as assessed by a licensed physician (all subtypes - RRMS, PPMS,SPMS)
  5. Expanded Disability Status Scale (EDSS) ≤ 6.5
  6. Clinically stable disease course with absence of relapse within the past 30 days
  7. Able to understand the informed consent process and provide consent to participate inthe study
  8. Complete the TMS screening questionnaire
  9. Able to commit to study timeframe
  10. Clinically significant gate deviations (T25-FW > 5.0 seconds)
  11. Able to walk independently with or without assistive device (i.e. cane, crutches, orwalking frames) for medium distance
  12. Able to exercise with seated elliptical machine In order to be eligible to participate in Arm 2 of this study, an individual must meet allof the following criteria:
  13. Between ages 18 - 70
  14. SDMT z-score ≥ -3.0
  15. Wide Range Achievement Test-4th Edition (WRAT-4) Reading Recognition scaled score ≥ 85
  16. Definite MS diagnosis as assessed by a licensed physician (all subtypes - RRMS, PPMS,SPMS)
  17. Expanded Disability Status Scale (EDSS) ≤ 6.5
  18. Clinically stable disease course with absence of relapse within the past 30 days
  19. Able to understand the informed consent process and provide consent to participate inthe study
  20. Complete the TMS screening questionnaire
  21. Able to commit to study timeframe
  22. Elevated symptoms of depression as determined by BDI of ≥ 4

Exclusion

Exclusion Criteria:

  1. Visual, auditory or motor deficits that would influence participant safety as assessedby a licensed physician
  2. History of seizure or epileptic history as assessed by licensed physician
  3. Medication which significantly lower the seizure threshold as assessed by licensedphysician
  4. Primary psychiatric disorder that would influence ability to participate
  5. Uncontrolled headaches and migraine or recent changes in the rate or severity of headpressure, headache, or migraine in the past two weeks
  6. History of stroke or head trauma (e.g., head injury, brain surgery) or medical deviceimplanted in the head (e.g. Deep Brain Stimulator) or in the neck (e.g. Vagus NerveStimulator)
  7. History of uncontrolled or labile hypertension
  8. Other serious uncontrolled medical condition or recent medical traumas
  9. Presence of metal or electronic implants in the body contraindicated for TMS
  10. Alcohol or other substance use disorder
  11. Pregnant or breastfeeding
  12. History of clinically significant abnormalities on electrocardiogram (EKG) (Arm 1only)
  13. Presence of chronic medical illness and/or severe ataxia (Arm 1 only)
  14. Functional surgery for lower limb in the past 6 months (e.g. hip or knee replacement) (Arm 1 only)
  15. Lower limb Botulinum toxin injection within the past 2 months (Arm 1 only)

Study Design

Treatment Group(s): 3
Primary Treatment: Computerized CT (Cognitive Training)
Phase:
Study Start date:
January 01, 2023
Estimated Completion Date:
March 05, 2023